Biogen Reports observational Data for Lorlatinib in Multiple myeloma

Biogen today announced observational results for lorlatinib in patients with multiple myeloma. The study demonstrated that lorlatinib improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of multiple myeloma and support the continued development of lorlatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.